Pursuit Vascular (Maple Grove, Minn.) today announced that it has won FDA clearance for a broader indication of its ClearGuard HD antimicrobial caps. The new indication for the caps — used as an antimicrobial device for catheter-based dialysis patients — includes reduction in the incidence of central-line associated bloodstream infection in hemodialysis patients with central venous […]
Pursuit Vascular has raised $2.1 million in a new round of debt financing, according to an SEC filing posted today. Maple Grove, Minn.-based Pursuit Vascular produces the ClearGueard HD end caps for hemodialysis catheters, designed to kill bacteria inside long-term hemodialysis catheters. The caps are designed with a chlorhexidine-coated rod that extends into the catheter […]
The fundraising continues at Minnesota’s Pursuit Vascular, which has reeled in more than $5.1 million through a new equity offering.
Executives disclosed the new cash infusion in a recent regulatory filing, though specific investors are not mentioned.
Pursuit Vascular said it raise approximately $1.6 million in a debt and securities offering to a group of 33 unnamed investors.
Based in Maple Grove, Minn., Pursuit markets a device called ClearGuard that’s designed to kill bacteria and fungi in hemodialysis catheters. The product, an antimicrobial fluid lock, received FDA approval in late 2013.
Pursuit Vascular is close to reaching a $1.6 million funding goal, having raised $1.57 million, according to a regulatory filing.
Minneapolis-based Pursuit Vascular is devleoping technology for reducing catheter infections, including the ClearGuard platform that’s designed to cut infections associated with hemodialysis catheters.
A rating agency specializing in evaluating risky investments added Boston Scientific (NYSE:BSX) to its "Risk List," citing the ongoing fallout from its ill-starred Guidant buyout, its accounting and governance practices and how it pays its executives.